Eikon Therapeutics, Inc. $EIKN Shares Newly Bought by Regents of The University of California

Regents of The University of California acquired a new stake in Eikon Therapeutics, Inc. (NASDAQ:EIKN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 635,131 shares of the company’s stock, valued at approximately $5,106,000. Eikon Therapeutics accounts for about 0.1% of Regents of The University of California’s holdings, making the stock its 9th biggest position. Regents of The University of California owned 1.17% of Eikon Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of EIKN. Legal & General Group Plc acquired a new stake in Eikon Therapeutics during the second quarter worth about $28,000. The Manufacturers Life Insurance Company lifted its holdings in Eikon Therapeutics by 23.5% in the second quarter. The Manufacturers Life Insurance Company now owns 35,357 shares of the company’s stock valued at $461,000 after acquiring an additional 6,734 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Eikon Therapeutics in the second quarter valued at approximately $142,000. Citadel Advisors LLC acquired a new position in Eikon Therapeutics in the second quarter valued at approximately $170,000. Finally, Deutsche Bank AG acquired a new position in Eikon Therapeutics in the second quarter valued at approximately $281,000.

Eikon Therapeutics Stock Up 0.2%

EIKN opened at $5.55 on Wednesday. Eikon Therapeutics, Inc. has a twelve month low of $5.44 and a twelve month high of $17.40. The company has a 50-day moving average price of $8.96 and a 200 day moving average price of $10.35. The company has a market cap of $300.62 million and a PE ratio of -1.36.

Eikon Therapeutics (NASDAQ:EIKN) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02). As a group, sell-side analysts expect that Eikon Therapeutics, Inc. will post -7.26 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Group Iv Gp Lp Column bought 89,200 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were acquired at an average price of $11.56 per share, for a total transaction of $1,031,152.00. Following the completion of the transaction, the insider directly owned 89,200 shares in the company, valued at $1,031,152. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Wedbush dropped their price objective on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a research note on Friday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eikon Therapeutics in a report on Friday, August 21st. Mizuho upgraded shares of Eikon Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 16th. Weiss Ratings raised shares of Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. Finally, HC Wainwright began coverage on shares of Eikon Therapeutics in a report on Friday, October 16th. They set a “buy” rating and a $23.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Eikon Therapeutics Profile

Eikon Therapeutics is a biotechnology company focused on discovering and developing medicines by combining advanced live-cell imaging with computational and biological research. Its technology platform is designed to observe the behavior of individual proteins in living cells, helping researchers investigate disease mechanisms and identify potential therapeutic targets.

The company applies this platform to drug discovery and development, with an emphasis on oncology and other serious diseases.